Insulin binding and glucose transport in adipocytes of acarbose-treated Zucker lean and obese rats.
The intestinal glucosidase inhibitor acarbose was administered as a dietary admix (30 mg/100 g chow diet) to male Zucker obese and lean rats. After 15 weeks, epidiymal fat pads were removed and adipocytes isolated by collagenase digestion. Equilibrium binding of A-14 tyrosine 125I-insulin, and transport of U-14C-glucose was determined was adipocytes incubated for 50 min at 37 degrees C in 0-16000 pM insulin. Insulin binding/cell was enhanced two-fold in lean (P less than 0.01) and obese (n.s.) drug groups. In drug-treated leans, increased sensitivity of glucose transport to submaximally stimulating concentrations of insulin was observed (P less than 0.02). For both genotypes, acarbose mildly decreased insulin levels and body weight gain, although adipocyte size was unaffected. Results indicate that enhanced insulin binding accompanies metabolic improvements induced by acarbose in lean Zucker rats.
Vasselli
J R
JR
Obesity Research Center, St Luke's-Roosevelt Hospital Center, New York, NY 10025.
Flory
T
T
Fried
S K
SK
D020909:Acarbose; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D005947:Glucose / Q000378:metabolism*; D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin / Q000378:metabolism*; D009765:Obesity / Q000378:metabolism; D051381:Rats; D011924:Rats, Zucker; D014312:Trisaccharides / Q000494:pharmacology*
D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin; D014312:Trisaccharides; D005947:Glucose; D020909:Acarbose